AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RACE ONCOLOGY LTD

2.100

0.000

Volume:65.57K

Turnover:138.38K

Market Cap:411.74M

PE:-38.85

High:2.160

Open:2.100

Low:2.030

Close:2.100

52wk High:4.900

52wk Low:1.180

Shares:196.07M

Float Shares:121.21M

Volume Ratio:0.93

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.028

ROE:-42.40%

ROA:-21.91%

PB:17.47

PE(LYR):-75.63

Loading ...

Overview Company News Filings

Racura Oncology Says Safety Review Committee Completes Review of HARNESS-1 Trial Single-Patient First Group Safety Data

MT Newswires Live

Racura Oncology Secures Ethics Committee Approval for Lung Cancer Clinical Trial for Trial Sites Outside Victoria

MT Newswires Live

Racura Oncology Doses First Patient in Phase 1 Trial of Lung Cancer Drug Candidate

MT Newswires Live

BUZZ-Australia's Racura Oncology jumps most in a month after raising $24 million

Racura Oncology Raises AU$34 Million to Fund Three Clinical Trials; Shares Up 3%

MT Newswires Live

Racura Oncology - Raises a$34.3 Mln to Fund Three Oncology Clinical Trials

THOMSON REUTERS

Racura Oncology Raises Over AU$24 Million Via Piggyback Option Offer; Shares Jump 6%

MT Newswires Live

BRIEF-Racura Oncology Says Emerging Companies Specialist Invests In Racura

Race Oncology Raises AU$1 Million in Strategic Placement

MT Newswires Live

Racura Oncology Ltd - Emerging Companies Specialist Invests in Racura

THOMSON REUTERS

Racura Oncology - Placement of 526,315 Fully Paid Ordinary Shares at Issue Price of a$1.90 per Share

THOMSON REUTERS

Racura Oncology - Placement, Combined With Funds From Piggyback and Bonus Options, Raised a$31.2 Mln to Support Clinical Development of Rc220

THOMSON REUTERS

Racura Oncology Ltd-Racura Enters Underwriting Agreement for Options

THOMSON REUTERS

Racura Oncology Ltd-Racura Oncology Final Option Expiry Reminder

THOMSON REUTERS

Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial

Racura Oncology advances RC220 CPACS trial after SRC clears Cohort 1 safety

Racura Oncology Ltd - to Initiate Screening for Cohort 2 at 80Mg/M2 Rc220 Dose Level

THOMSON REUTERS

Racura Oncology Ltd - No Safety Concerns Noted With Rc220 Alone or With Doxorubicin in First Cohort

THOMSON REUTERS

Racura Oncology Announces Positive Safety Review Committee Recommendation in Ongoing Cpacs Clinical Trial

THOMSON REUTERS

Racura Oncology Receives Clearance to Advance Dose Level in Phase One Cardioprotection, Anticancer Synergy Trial

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/RAC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":2.1,"timestamp":1787292720000,"preClose":2.1,"halted":0,"volume":65569,"delay":0,"changeRate":0,"nameEN":"RACE ONCOLOGY LTD","floatShares":121205750,"shares":196068940,"eps":-0.054053,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:12:00 AEST","open":2.1,"high":2.16,"low":2.03,"amount":138375,"amplitude":0.061905,"askPrice":2.12,"askSize":1888,"bidPrice":2.06,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.054053,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.1,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":0.9282791832858144,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAC.AU","preClose":2.1,"auctionPrice":2.1,"auctionVolume":220,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600775}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":121205750,"roa":"-21.91%","roe":"-42.40%","lyrEps":-0.027765,"volumeRatio":0.9282791832858144,"shares":196068940,"dividePrice":0,"high":2.16,"amplitude":0.061905,"preClose":2.1,"low":2.03,"week52Low":1.18,"pbRate":"17.47","psRate":"118.43","week52High":4.9,"institutionHeld":0,"latestPrice":2.1,"committee":0.4518,"eps":-0.054053,"divideRate":0,"volume":65569,"delay":0,"ttmEps":-0.054053,"open":2.1,"prevYearClose":2.73,"prevWeekClose":1.995,"prevMonthClose":1.95,"prevQuarterClose":2.22,"fiveDayClose":1.995,"twentyDayClose":2.05,"sixtyDayClose":2.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655834301","title":"Racura Oncology Says Safety Review Committee Completes Review of HARNESS-1 Trial Single-Patient First Group Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2655834301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655834301?lang=en_us&edition=fundamental","pubTime":"2026-07-29 08:46","pubTimestamp":1785286003,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the Safety Review Committee completed its review of safety data from the HARNESS-1 trial single-patient first group who received a dose of its RC220 drug candidate at 50 milligrams per square meter with osimertinib 80 milligrams daily, according to a Wednesday Australian bourse filing.No dose-limiting toxicities or treatment-related safety concerns were identified during the safety observation period. However, the patient reported moderate symptoms consistent with colitis, an inflammation of the large intestine or colon, after the period ended. The cause of these symptoms has not yet been determined, and clinical investigations are ongoing.The observed colitis was not considered a dose-limiting toxicity or treatment-related adverse event. However, the committee recommended that one additional patient receive the drug candidate at 50 milligrams per square meter with 80 milligrams of osimertinib before dose escalation to 100 mg/m2 occurs, as a prudent precaution.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648310506","title":"Racura Oncology Secures Ethics Committee Approval for Lung Cancer Clinical Trial for Trial Sites Outside Victoria","url":"https://stock-news.laohu8.com/highlight/detail?id=2648310506","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648310506?lang=en_us&edition=fundamental","pubTime":"2026-07-03 08:30","pubTimestamp":1783038637,"startTime":"0","endTime":"0","summary":"Racura Oncology  said the Bellberry human research ethics committee approved the HARNESS-1 lung cancer clinical trial, for Australian private hospital sites and eligible public hospital sites outside Victoria, allowing for additional clinical trial sites to be activated, according to a Friday Australian bourse filing.The study is evaluating the safety, tolerability, and pharmacokinetics of RC220, the firm's proprietary formulation of bisantrene, in combination with osimertinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutations. Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations.The human research ethics committee for the St Vincents Hospital in Melbourne had earlier approved the lead clinical trial site, Monash Health. The hospital committee also approved the inclusion of Austin Health in Victoria.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4095","VCCTF","RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646844292","title":"Racura Oncology Doses First Patient in Phase 1 Trial of Lung Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2646844292","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646844292?lang=en_us&edition=fundamental","pubTime":"2026-06-25 07:18","pubTimestamp":1782343113,"startTime":"0","endTime":"0","summary":"Racura Oncology  dosed the first patient in a phase 1 clinical trial evaluating its RC220 drug candidate in combination with osimertinib for the treatment of non-small cell lung cancer, according to a Thursday filing with the Australian bourse.The company said no adverse events were seen during or after the first RC220 infusion.The study is using single-patient cohorts for the first three dose escalation stages before advancing to larger cohorts to determine the maximum tolerated dose. Additional clinical trial sites are expected to open in the coming months.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643773534","title":"BUZZ-Australia's Racura Oncology jumps most in a month after raising $24 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643773534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643773534?lang=en_us&edition=fundamental","pubTime":"2026-06-16 12:24","pubTimestamp":1781583872,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Racura Oncology jumps most in a month after raising $24 million** Australia's Racura Oncology RAC.AX rises as much as 13.2% to A$2.66, its biggest one-day gain since May 15** Biopharm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL6N42O09X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643738762","title":"Racura Oncology Raises AU$34 Million to Fund Three Clinical Trials; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643738762","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643738762?lang=en_us&edition=fundamental","pubTime":"2026-06-16 11:16","pubTimestamp":1781579796,"startTime":"0","endTime":"0","summary":"Racura Oncology  raised AU$34.3 million in total to fund three RC220 clinical trials in acute myeloid leukemia, epidermal growth factor receptor mutant lung cancer, and chemotherapy-related cardio-protection in solid tumor patients, according to a Tuesday filing with the Australian bourse.RC220 is the company's formulation of (E,E)-bisantrene, a small molecule anti-cancer agent, the filing said.The company has raised the funds since June 2024 through bonus and piggyback option conversions, private placements, and option underwriting, per the filing.Shares rose 3% in afternoon trade on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643738815","title":"Racura Oncology - Raises a$34.3 Mln to Fund Three Oncology Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2643738815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643738815?lang=en_us&edition=fundamental","pubTime":"2026-06-16 10:36","pubTimestamp":1781577389,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42O004:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640365601","title":"Racura Oncology Raises Over AU$24 Million Via Piggyback Option Offer; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640365601","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640365601?lang=en_us&edition=fundamental","pubTime":"2026-06-04 10:33","pubTimestamp":1780540389,"startTime":"0","endTime":"0","summary":"Racura Oncology  said it generated proceeds of about AU$24.4 million after a total of 19.5 million piggyback options were exercised out of the 20.1 million issued at its piggyback option offer, representing a 97% conversion rate, according to a Thursday Australian bourse filing.The proceeds provide additional capital to advance the company's clinical programs in acute myeloid leukemia, lung cancer, and anthracycline cardioprotection, as well as general working capital, per the filing.The company's shares rose nearly 6% in recent trading on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RAC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640133375","title":"BRIEF-Racura Oncology Says Emerging Companies Specialist Invests In Racura","url":"https://stock-news.laohu8.com/highlight/detail?id=2640133375","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640133375?lang=en_us&edition=fundamental","pubTime":"2026-06-04 09:08","pubTimestamp":1780535288,"startTime":"0","endTime":"0","summary":"BRIEF-Racura Oncology Says Emerging Companies Specialist Invests In RacuraJune 4  - Racura Oncology Ltd RAC.AX:EMERGING COMPANIES SPECIALIST INVESTS IN RACURAPLACEMENT OF 526,315 FULLY PAID ORDINARY SHARES AT ISSUE PRICE OF A$1.90 PER SHAREPLACEMENT, COMBINED WITH FUNDS FROM PIGGYBACK AND BONUS OPTIONS, RAISED A$31.2 MILLION TO SUPPORT CLINICAL DEVELOPMENT OF RC220Further company coverage: RAC.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42B10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640180306","title":"Race Oncology Raises AU$1 Million in Strategic Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640180306","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640180306?lang=en_us&edition=fundamental","pubTime":"2026-06-04 07:33","pubTimestamp":1780529612,"startTime":"0","endTime":"0","summary":"Race Oncology  secured around AU$1 million via a targeted private placement with a specialist healthcare-focused institutional investor, issuing 526,315 fully paid ordinary shares at AU$1.90 each, representing a 23% discount to its recent average market price, according to a Thursday filing with the Australian bourse.The company has raised a total of AU$31.2 million, including this placement and recent funds from piggyback and bonus option offers, to support the clinical development of RC220 and general working capital requirements, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640874301","title":"Racura Oncology Ltd - Emerging Companies Specialist Invests in Racura","url":"https://stock-news.laohu8.com/highlight/detail?id=2640874301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640874301?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:51","pubTimestamp":1780527068,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B10D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640187432","title":"Racura Oncology - Placement of 526,315 Fully Paid Ordinary Shares at Issue Price of a$1.90 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2640187432","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640187432?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:51","pubTimestamp":1780527068,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B10D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","RAC.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640118745","title":"Racura Oncology - Placement, Combined With Funds From Piggyback and Bonus Options, Raised a$31.2 Mln to Support Clinical Development of Rc220","url":"https://stock-news.laohu8.com/highlight/detail?id=2640118745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640118745?lang=en_us&edition=fundamental","pubTime":"2026-06-04 06:51","pubTimestamp":1780527068,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nFWN42B10D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638565030","title":"Racura Oncology Ltd-Racura Enters Underwriting Agreement for Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2638565030","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638565030?lang=en_us&edition=fundamental","pubTime":"2026-05-28 14:43","pubTimestamp":1779950591,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUE7XNKM9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637714988","title":"Racura Oncology Ltd-Racura Oncology Final Option Expiry Reminder","url":"https://stock-news.laohu8.com/highlight/detail?id=2637714988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637714988?lang=en_us&edition=fundamental","pubTime":"2026-05-21 07:34","pubTimestamp":1779320069,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUE8VM2RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086048","title":"Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086048","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086048?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:21","pubTimestamp":1778844111,"startTime":"0","endTime":"0","summary":"Racura Oncology Ltd ::*RACURA ONCOLOGY ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE RECOMMENDATION IN ONGOING CPACS CLINICAL TRIAL*RACURA ONCOLOGY LTD - NO SAFETY CONCERNS NOTED WITH RC220 ALONE OR WITH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nRSD7V0zk3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086992","title":"Racura Oncology advances RC220 CPACS trial after SRC clears Cohort 1 safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086992?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:06","pubTimestamp":1778843211,"startTime":"0","endTime":"0","summary":"Racura Oncology reported May 15, 2026 that an independent Safety Review Committee recommended continuing CPACS, an ongoing trial of RC220 alone or combined with doxorubicin in advanced metastatic solid tumors.Results have already been reviewed by the committee, with no safety concerns flagged in first cohort, supporting continued dosing in subsequent groups.Company plans to move to Cohort 2 screening at higher RC220 dose, shifting trial design to include an initial doxorubicin-only cycle to help assess potential cardioprotection.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4qsdLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635869510","title":"Racura Oncology Ltd - to Initiate Screening for Cohort 2 at 80Mg/M2 Rc220 Dose Level","url":"https://stock-news.laohu8.com/highlight/detail?id=2635869510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635869510?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:06","pubTimestamp":1778843191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA9GGLTN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086967","title":"Racura Oncology Ltd - No Safety Concerns Noted With Rc220 Alone or With Doxorubicin in First Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086967?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:06","pubTimestamp":1778843191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA9GGLTN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","RAC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086954","title":"Racura Oncology Announces Positive Safety Review Committee Recommendation in Ongoing Cpacs Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635086954?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:06","pubTimestamp":1778843191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA9GGLTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635727026","title":"Racura Oncology Receives Clearance to Advance Dose Level in Phase One Cardioprotection, Anticancer Synergy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635727026","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635727026?lang=en_us&edition=fundamental","pubTime":"2026-05-15 08:23","pubTimestamp":1778804610,"startTime":"0","endTime":"0","summary":"Racura Oncology  received clearance from the Safety Review Committee to advance the RC220 dose in the first-phase Cardioprotection and Anticancer Synergy trial to the next designated dose level of 80 milligrams per square meter, according to a Friday filing with the Australian bourse.RC220 is the company's formulation of the anticancer agent (E,E)-bisantrene.The approval comes following confirmation that the drug showed an acceptable safety profile, with no dose-limiting toxicities or safety concerns noted during the observation period for the first three group one patients dosed at 40 milligrams per square meter, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAC.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}